Control of (Multi)Drug Resistance and Tuberculosis Incidence over 23 Years in the Context of a Well-Supported Tuberculosis Programme in Rural Malawi

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Mboma, Sebastian M ^a   Houben, Rein M G J ^a,b   Glynn, Judith R ^b   Sichali, Lifted ^a   Drobniewski, Francis ^e   Mpunga, James ^c   Fine, Paul E M ^b   French, Neil ^d   Crampin, Amelia C ^a,b  

^a KARONGA PREVENTION STUDY   (Malawi)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c National TB Control Programme   (Malawi)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG EFFICACY; DRUG SENSITIVITY; EPIDEMIC; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MAJOR CLINICAL STUDY; MALAWI; MALE; MEDICAL INFORMATION; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; RURAL AREA; SHORT COURSE THERAPY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

COMMUNICABLE DISEASE CONTROL; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MULTIPLE; HIV INFECTIONS; HUMANS; INCIDENCE; MALAWI; PREVALENCE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84874621231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058192     Document Type: Article

References (33)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
2. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD, (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374: 921-933.
3. Lukoye D, Cobelens FG, Ezati N, Kirimunda S, Adatu FE, et al. (2011) Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS One 6: e16130.
4. Mulenga C, Chonde A, Bwalya IC, Kapata N, Kakungu-Simpungwe M, et al. (2010) Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia. Tuberc Res Treat 2010: 938178.
5. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, et al. (1999) Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 3: 4-11.
6. Talbot EA, Kenyon TA, Mwasekaga MJ, Moeti TL, Mallon V, et al. (2003) Control of anti-tuberculosis drug resistance in Botswana. Int J Tuberc Lung Dis 7: 72-77.
7. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, et al. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373: 1861-1873.
8. Evans CA, (2011) GeneXpert-a game-changer for tuberculosis control? PLoS Med 8: e1001064.
9. Lawn SD, Kerkhoff AD, Wood R, (2012) Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 16: 701.
10. Peters D, Theron G, Peter J, Dheda K, (2012) Should Xpert(R) MTB/RIF be rolled out in low-income countries? Int J Tuberc Lung Dis 16: 702-703.
11. Trebucq A, Harries AD, (2012) In reply to 'Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact'. Int J Tuberc Lung Dis 16: 702.
12. Trebucq A, Harries AD, Rieder HL, (2012) In reply to 'Should Xpert(R) MTB/RIF be rolled out in low-income countries?'. Int J Tuberc Lung Dis 16: 703-704.
13. Trebucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, et al. (2011) Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 15: 1567-1572.
14. WHO (2010) Global tuberculosis control: WHO report 2010. Geneva: World Health Organisation.
15. Crampin AC, Glynn JR, Fine PE, (2009) What has Karonga taught us? Tuberculosis studied over three decades. International Journal of Tuberculosis & Lung Disease 13: 153-164.
16. Floyd S, Molesworth A, Dube A, Banda E, Jahn A, et al. (2010) Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi. PLoS One 5: e13499.
17. Glynn JR, Crampin AC, Ngwira BM, Mwaungulu FD, Mwafulirwa DT, et al. (2004) Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001. Aids 18: 1459-1463.
18. Glynn JR, Jenkins PA, Fine PE, Ponnighaus JM, Sterne JA, et al. (1995) Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. Lancet 345: 907-910.
19. Warndorff DK, Yates M, Ngwira B, Chagaluka S, Jenkins PA, et al. (2000) Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986-1998. Int J Tuberc Lung Dis 4: 752-757.
20. Mwaungulu FD, Crampin AC, Kanyongoloka H, Mwafulirwa DT, Mwaungulu JN, et al. (2002) Antituberculosis drug resistance in Karonga District: pattern and trend, 1986-2001. Malawi Medical Journal 13: 3-6.
21. Malawi Population and Housing Census. Zomba: National Statistics Office, Malawi.
22. White RG, Vynnycky E, Glynn JR, Crampin AC, Jahn A, et al. (2007) HIV epidemic trend and antiretroviral treatment need in Karonga District, Malawi. Epidemiol Infect 135: 922-932.
23. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, et al. (2008) Population-level effect of HIV an adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371: 1603-1611.
24. Ponnighaus JM, Fine PE, (1986) The Karonga prevention trial-which BCG? Lepr Rev 57Suppl 2: 285-292.
25. Ponnighaus JM, Fine PE, Bliss L, Gruer PJ, Kapira-Mwamondwe B, et al. (1993) The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malawi. I. Methods of the vaccination phase. Lepr Rev 64: 338-356.
26. Cuevas LE, Yassin MA, Al-Sonboli N, Lawson L, Arbide I, et al. (2011) A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med 8: e1000443.
27. Ngwira B, Chagaluka S, Warndorff D, Branson K, Lucas S, et al. (2002) Development of a scoring system for the diagnosis of tuberculous lynphadenitis. Malawi Med J 13: 14-16.
28. WHO (2009) Guidelines for surveillance of drug resistance in tuberculosis, 4th Edition. Geneva: World Health Organisation.
29. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, et al. (1993) Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406-409.
30. Glynn JR, Crampin AC, Yates MD, Traore H, Mwaungulu FD, et al. (2005) The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi. J Infect Dis 192: 480-487.
31. NTP (2007) Malawi National Tuberculosis Control Programme Manual 6th Edition.
32. Glynn JR, Crampin AC, Traore H, Chaguluka S, Mwafulirwa DT, et al. (2008) Determinants of cluster size in large, population-based molecular epidemiology study of tuberculosis, northern Malawi. Emerg Infect Dis 14: 1060-1066.
33. Crampin AC, Floyd S, Mwaungulu F, Black G, Ndhlovu R, et al. (2001) Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis 5: 994-999.